Eris Lifesciences

Rediff.com » News » Eris Lifesciences

News for Eris Lifesciences

Business

Pricing challenge in US biz, rich valuations may weigh on pharma stocks

The tailwind of low price erosion in the US generics market, seen by domestic pharmaceutical companies in calendar year 2023 (CY23), may be reversing slowly, caution analysts. Illustration: Uttam......

'Expect formulations biz to outpace API biz'

'API prices are dragging down margins and impacting our competitive ability.' Photograph: Kind courtesy Biocon Biocon delves into the evolving dynamics of the biosimilar market, with a focus on......

Q3 result preview: US, India to aid revenue growth for Pharma Inc

The pharmaceuticals sector is expected to post a revenue growth of around 13.5 per cent and a net profit growth of 30.3 per cent for the third quarter of 2023-24 (FY24), riding on the approval for......

India's pharma industry likely to take 5-6% price hikes this year

Notwithstanding the fact that the country’s pharmaceutical (pharma) pricing regulator has allowed a 12 per cent price increase for medicines listed under the National List of Essential......

Big drugmakers step in to develop, import test kits

Cadila, Biocon developing rapid antibody testing kits; Eris, Mylan, Gland importing. Indian pharma majors are gearing up to develop or import testing kits for the novel coronavirus as demand for......

Rediff News

Eris Lifesciences

News for Eris Lifesciences

Pricing challenge in US biz, rich valuations may weigh on pharma stocks

'Expect formulations biz to outpace API biz'

Q3 result preview: US, India to aid revenue growth for Pharma Inc

India's pharma industry likely to take 5-6% price hikes this year

Big drugmakers step in to develop, import test kits

Top Coverage News

World Test Championship 2023

Manipur's Tragedy

IPL 2023

Sri Lanka's Tour of India 2023

GUJARAT, HIMACHAL GO TO POLLS